PART I Corporate Overview We incorporated in the State of Nevada on May 2, 2011, and are presently based in the County of San Diego, California. We are a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system (the ECS), a network of receptors and neurotransmitters that form a biochemical communication system throughout the body. Our product candidate pipeline b...
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001640334-26-000368 | EDGAR | 76K words |
| 2025-03-03 | 2024-12-31 | 0001640334-25-000335 | EDGAR | — |
| 2024-03-25 | 2023-12-31 | 0001640334-24-000473 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001640334-23-000509 | EDGAR | — |
| 2021-11-29 | 2021-08-31 | 0001640334-21-002983 | EDGAR | — |
| 2020-11-04 | 2020-08-31 | 0001640334-20-002722 | EDGAR | — |
| 2019-11-25 | 2019-08-31 | 0001640334-19-002443 | EDGAR | — |
| 2018-11-29 | 2018-08-31 | 0001640334-18-002309 | EDGAR | — |
| 2017-11-29 | 2017-08-31 | 0001640334-17-002551 | EDGAR | — |
| 2016-11-29 | 2016-08-31 | 0001640334-16-002136 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001640334-25-002022 | EDGAR | 22K words |
| 2025-08-13 | 2025-06-30 | 0001640334-25-001429 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001640334-25-000825 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001640334-24-001677 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001640334-24-001221 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001640334-24-000757 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001640334-23-002073 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001640334-23-001504 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001640334-23-000804 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001640334-22-002363 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001640334-22-001681 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001640334-22-000949 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001640334-26-000574 | EDGAR | 23K words |
| 2026-03-26 | 0001640334-26-000554 | EDGAR | — |
| 2026-03-18 | 0001640334-26-000475 | EDGAR | — |
| 2026-03-17 | 0001640334-26-000461 | EDGAR | — |
| 2026-03-06 | 0001640334-26-000395 | EDGAR | — |
| 2026-02-05 | 0001640334-26-000227 | EDGAR | — |
| 2026-02-05 | 0001640334-26-000221 | EDGAR | — |
| 2026-01-30 | 0001640334-26-000181 | EDGAR | — |
| 2026-01-16 | 0001640334-26-000109 | EDGAR | — |
| 2026-01-02 | 0001640334-26-000005 | EDGAR | — |
192 total filings indexed. 160 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001621221 |
| Ticker | ARTL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.artelobio.com |
| Listed | 2015-10-13 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report